SK Pharmteco’s headquarters in Sacramento, California
SK Inc., the holding and investment company of SK Group, South Korea’s second-largest conglomerate, is negotiating to sell a major asset of its contract drug-making unit SK Pharmteco Co. in the US to Novo Nordisk A/S, a Danish multinational pharmaceutical company.
SK is in final-stage talks to sell SK Pharmteco’s contract development and manufacturing organization (CDMO) factory in Petersburg, Virginia to Novo Nordisk, people familiar with the matter said on Tuesday.
Sources said that the deal’s value is estimated to be 300 billion won ($216 million).
The two sides aim to complete the deal by the end of August, they said.
SK Pharmteco operates CDMO plants in California, Virginia and Texas.
(Graphics by Dongbeom Yun)
Industry officials said the contract drug-making facilities boast high quality and yields that the US government picked SK Pharmteco as one of the strategic medical suppliers during the COVID-19 pandemic.
Known for Wegovy, a weight-loss medicine, Novo Nordisk is expanding its pharmaceutical business by purchasing companies with which it has worked under the contract manufacturing organization (CMO) scheme.
In February, its holding firm Novo Holdings A/S acquired Catalent Inc., a leading CDMO company, for $16.5 billion.
Novo plans to spend an extra $4.1 billion to enhance its presence in the US through mergers and acquisitions, according to media reports.
SK Pharmteco’s CDMO plant in Virginia
SK EXPECTS HANDSOME GAINS
If talks with Novo Nordisk go smoothly, SK Inc. is expected to make a profit at least 10 times its purchase price, sources said.
SK Pharmteco will likely use the sales proceeds to invest in its cell and gene therapy (CGT) business, they said.
In 2021, SK Inc. purchased a 70% stake in Yposkesi, a French biopharmaceutical company, to advance into the cell and gene therapy business, from Genethon.
The following year, SK became the second-largest stakeholder in the Center for Breakthrough Medicines (CBM), a US-based cell therapy developer and CDMO, after investing $350 million.
In 2017, SK acquired Bristol-Myers Squibb (BMS)’s manufacturing facility in Ireland and in the following year, it took over California-based AMPAC Fine Chemicals, a CDMO.
SK Pharmteco’s global presence
SK Group established SK Pharmteco in 2019 to oversee its growing portfolio of pharma manufacturing facilities and businesses.
SK Pharmteco posted 89 billion won in operating losses on sales of 812 billion won in 2023.
BUSINESS REBALANCING
The sale of an SK Pharmteco plant comes as part of SK Group’s aggressive corporate restructuring to reduce the number of its affiliates and explore new growth drivers.
Industry sources said on Monday that SK is putting up for sale its 25% stake in Korea Superfreeze Inc., a cold chain logistics company jointly owned by EMP Belstar and Goldman Sachs.
SK Group’s headquarters in Seoul
The conglomerate is also seeking to combine SK Ecoplant Co., a construction engineering and waste management firm, with SK Materials Co., an industrial gas business unit, to create synergy.
Last week, sources said SK Group plans to merge SK Innovation Co., the parent of Korea’s largest oil refiner SK Energy Co. and battery maker SK On Co., with energy affiliate SK E&S Co.
The group is also seeking funds from the state-run Korea Development Bank (KDB) to finance its restructuring efforts.
By Hyung-Kyu Kim, Jeong-Min Nam and Ji-Eun Ha
khk@hankyung.com
In-Soo Nam edited this article.
